Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Glycomimetics Inc.
Headquarters: Rockville, MD, United States of America
Website: http://www.glycomimetics.com...
Year Founded: 2003
Status: Public
Industry Sector: HealthTechnology
CEO: Harout Semerjian, MBA
Number Of Employees: 26
Enterprise Value: $5,401,501
PE Ratio: -0.31
Exchange/Ticker 1: NASDAQ:GLYC
Exchange/Ticker 2: N/A
Latest Market Cap: $11,857,700
BioCentury | Apr 4, 2025
Management Tracks
Ex-Dyne team members reconvene at Crescent
Plus: New staff at Neurocrine, Xaira and Dark Blue; Oz confirmed at CMS
BioCentury | Nov 26, 2024
Management Tracks
Susanna High named CEO of Paragon
Plus: Lee Patterson becomes CEO of Metrion, and updates from Rondo, AffyImmune and Aspargo
BioCentury | Nov 14, 2024
Deals
Already partners on bispecific, BioNTech buys Biotheus for $800M
Along with potential Keytruda competitor, German biotech gains pipeline, bispecific platform, and China sites via acquisition
BioCentury | Nov 5, 2024
Deals
Novo to use Ascendis’ TransCon for once-monthly GLP-1R agonist
Deals report: AbbVie-EvolveImmune, Genmab-Revitope and GSK-Chimagen partner for T cell engagers
BioCentury | Nov 1, 2024
Finance
How Fairmount’s Paragon incubator steered two more companies to NASDAQ
In BioCentury’s Public Equity Report: Paragon-backed Jade and Crescent each reverse-merging with public companies, raising combined $500M
BioCentury | Oct 31, 2024
Emerging Company Profile
IHP: Creating an EpiPen for sickle cell disease
Company aims to keep patients out of hospital with a dual-mechanism rescue treatment to prevent vaso-occlusive crises
BioCentury | Sep 26, 2024
Product Development
Sickle cell mechanisms that could fill the hole left by Pfizer’s Oxbryta withdrawal
Following the market withdrawal of Pfizer’s Oxbryta, demand rises for sickle cell therapies with global potential
BioCentury | May 7, 2024
Product Development
Clinical report: Calliditas data provide mixed support for anti-fibrotic cancer mechanism
Plus: J&J aiming to replace bladder cancer surgery with TAR-210, and updates from Merck, GlycoMimetics, EyePoint and more
BioCentury | Mar 13, 2024
Management Tracks
IDRx names Clackson, Dahms to C-suite and Auspitz chair
Plus: new COO for radiopharma
BioCentury | Oct 25, 2023
Management Tracks
Korro promoting Chappell to COO, adding Pearson to board
Plus: 3T hires Irving and updates from Q32 Bio, Garuda and Fibrocor
Items per page:
1 - 10 of 133